AURA BIOSCIENCES INC (AURA) Stock Price & Overview
NASDAQ:AURA • US05153U1079
Current stock price
The current stock price of AURA is 6.58 USD. Today AURA is down by -3.38%. In the past month the price increased by 29.71%. In the past year, price decreased by -9.2%.
AURA Key Statistics
- Market Cap
- 417.83M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.94
- Dividend Yield
- N/A
AURA Stock Performance
AURA Stock Chart
AURA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to AURA. When comparing the yearly performance of all stocks, AURA turns out to be only a medium performer in the overall market: it outperformed 52.28% of all stocks.
AURA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AURA. No worries on liquidiy or solvency for AURA as it has an excellent financial health rating, but there are worries on the profitability.
AURA Earnings
AURA Forecast & Estimates
12 analysts have analysed AURA and the average price target is 18.87 USD. This implies a price increase of 186.78% is expected in the next year compared to the current price of 6.58.
AURA Groups
Sector & Classification
AURA Financial Highlights
Over the last trailing twelve months AURA reported a non-GAAP Earnings per Share(EPS) of -1.94. The EPS decreased by -10.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.03% | ||
| ROE | -67.96% | ||
| Debt/Equity | 0 |
AURA Ownership
AURA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.04 | 388.573B | ||
| AMGN | AMGEN INC | 15.39 | 194.674B | ||
| GILD | GILEAD SCIENCES INC | 15.98 | 179.261B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.29 | 117.486B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 80.247B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.19 | 42.494B | ||
| INSM | INSMED INC | N/A | 31.024B | ||
| NTRA | NATERA INC | N/A | 28.116B | ||
| BIIB | BIOGEN INC | 11.34 | 27.193B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.76 | 23.669B | ||
| MRNA | MODERNA INC | N/A | 21.299B | ||
| EXAS | EXACT SCIENCES CORP | 341.33 | 19.841B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.645B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AURA
Company Profile
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The company is headquartered in Boston, Massachusetts and currently employs 106 full-time employees. The company went IPO on 2021-10-29. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. The company is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
Company Info
IPO: 2021-10-29
AURA BIOSCIENCES INC
80 Guest Street
Boston MASSACHUSETTS US
CEO: Elisabet de los Pinos
Employees: 106
Phone: 16175008864
AURA BIOSCIENCES INC / AURA FAQ
Can you describe the business of AURA BIOSCIENCES INC?
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The company is headquartered in Boston, Massachusetts and currently employs 106 full-time employees. The company went IPO on 2021-10-29. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. The company is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
What is the current price of AURA stock?
The current stock price of AURA is 6.58 USD. The price decreased by -3.38% in the last trading session.
What is the dividend status of AURA BIOSCIENCES INC?
AURA does not pay a dividend.
How is the ChartMill rating for AURA BIOSCIENCES INC?
AURA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists AURA stock?
AURA stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of AURA BIOSCIENCES INC (AURA)?
AURA BIOSCIENCES INC (AURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.94).
Can you provide the number of employees for AURA BIOSCIENCES INC?
AURA BIOSCIENCES INC (AURA) currently has 106 employees.